This edition presents key opinion leader (KOL) views on recent developments in the ulcerative colitis (UC) market. Topics covered include: Takeda and Portal Instruments announcing the production of a needle-free formulation of Entyvio (vedolizumab); Qu Biologics reporting that QBECO achieved high clinical and endoscopic response ratesin a Phase II trial conducted in patients with moderate-to-severe UC; Protagonist Therapeutics announcing the initiation of dosing in a Phase I study of PTG 200, an agent which it is developing in collaboration with Janssen Biotech for inflammatory bowel disease (IBD) and other autoimmune conditions; Weill Cornell Medicine and NewYork-Presbyterian presenting results from a study investigating the use of faecal microbiota transplantation (FMT) in patients with UC.
Are the new formulations of Entyvio likely to provide any benefit to patients with UC?
Is the development of both a needle-free and subcutaneous formulation of Entyvio necessary?
Does QBECO’s composition, based on enteropathic Escherichia coli components, provide a rational basis for the agent’s development as a UC therapy?
Where is PTG 200 most likely to be positioned within the UC treatment algorithm in the future?
Do KOLs think that the scientific rationale underlying FMT’s activity supports its development as a treatment for UC and/or other diseases?
Do KOLs have any concerns about the safety of the FMT procedure?
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook